Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for Romidepsin (compound)
Most Correlated Studies
- Peripheral blood mononuclear cells of cutaneous T-cell lymphoma patients treated with romidepsin
- HCT116 colorectal carcinoma cells treated with HDAC inhibitors largazole, SAHA, and FK228
- Breast adenocarcinoma MCF7 cells treated with S2101, UNC0638, GSK343, romidepsin and decitabine
- Colorectal cancer YB5 cells treated with S2101, UNC0638, GSK343, romidepsin and decitabine
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
Most Relevant Literature
- Romidepsin antagonism with CHOEP.
- Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin.
- Romidepsin-induced durable remission for relapsed nodal peripheral T-cell lymphoma with T follicular…
- Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy…
- Changes in Electrocardiogram During Romidepsin Therapy: A Case Report.
Most Relevant Clinical Trials
- Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
- Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
- Long-term Use of Romidepsin in Patients With CTCL
- Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
- Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
